An advanced heart failure treatment material comprising a pharmaceutical agent, an agent holding the pharmaceutical agent, and a myocardial support device, wherein the pharmaceutical agent is an internal regeneration factor production inducing agent comprising a prostaglandin I 2 agonist indicated by the following general formula or a salt thereof: (in the formula, is (wherein, R 1 is a hydrogen atom or a C1-4 alkyl group, R 2 is (i) a hydrogen atom, (ii) a C1-8 alkyl group that may be branched or form a ring, (iii) a phenyl group or a C4-7 cycloalkyl group, (iv) a 4-7-membered single ring containing one nitrogen atom, (v) a C1-4 alkyl group substituted by a benzene ring or a C4-7 cycloalkyl group, or (vi) a C1-4 alkyl group substituted by a 4-7-membered single ring containing one nitrogen atom, R 3 is (i) a C1-B alkyl group that may be branched or form a ring, (ii) a phenyl group or a C4-7 cycloalkyl group, (iii) a 4-7-membered single ring containing one nitrogen atom, (iv) a C1-4 alkyl group substituted by a benzene ring or a C4-7 cycloalkyl group, or (v) a C1-4 alkyl group substituted by a 4-7-membered single ring containing one nitrogen atom, and e is an integer of 3-5, f is an integer of 1-3, p is an integer of 1-4, q is 1 or 2, and r is an integer of 1-3, provided that in a case where is a group indicated by (iii) or (iv), -(CH 2) p - and =CH-(CH 2) r - are bound to a or b on a ring, and a ring in R 2 and R 3 may be substituted by one to three C1-4 alkyl groups, C1-4 alkoxy groups, halogen atoms, nitro groups, or trihalomethyl groups), and wherein the agent holding the pharmaceutical agent is a sustained-release preparation holding agent, which comprises at least one high-molecular compound selected from the group consisting of fibrin, gelatin, collagen, and hyaluronic acid. R 1 is a hydrogen atom or a C1-4 alkyl group, R 2 is (i) a hydrogen atom, (ii) a C1-8 alkyl group that may be branched or form a ring, (iii) a phenyl group or a C4-7 cycloalkyl group, (iv) a 4-7-membered single ring containing one nitrogen atom, (v) a C1-4 alkyl group substituted by a benzene ring or a C4-7 cycloalkyl group, or (vi) a C1-4 alkyl group substituted by a 4-7-membered single ring containing one nitrogen atom, R 3 is (i) a C1-B alkyl group that may be branched or form a ring, (ii) a phenyl group or a C4-7 cycloalkyl group, (iii) a 4-7-membered single ring containing one nitrogen atom, (iv) a C1-4 alkyl group substituted by a benzene ring or a C4-7 cycloalkyl group, or (v) a C1-4 alkyl group substituted by a 4-7-membered single ring containing one nitrogen atom, and e is an integer of 3-5, f is an integer of 1-3, p is an integer of 1-4, q is 1 or 2, and r is an integer of 1-3, provided that in a case where is a group indicated by (iii) or (iv), -(CH 2) p - and =CH-(CH 2) r - are bound to a or b on a ring, and a ring in R 2 and R 3 may be substituted by one to three C1-4 alkyl groups, C1-4 alkoxy groups, halogen atoms, nitro groups, or trihalomethyl groups), and wherein the agent holding the pharmaceutical agent is a sustained-release preparation holding agent, which comprises at least one high-molecular compound selected from the group consisting of fibrin, gelatin, collagen, and hyaluronic acid.